Sugi Predict

Sugi Predict / Compounds / SCHEMBL1702229

SCHEMBL1702229

SCHEMBL1702229

C[C@@]1([C@H](O)C(CCc2ccccc2)NC(=O)OCc2ccccc2)CO1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 9/20 0.48
▸ CTSB P07858 2/20 0.46
▸ ATM Q13315 1/20 0.46
▸ TRPM8 Q7Z2W7 1/20 0.45
▸ CYP3A4 P08684 7/20 0.44
▸ TSHR P16473 6/20 0.44
▸ ALDH1A1 P00352 4/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ CASP1 P29466 1/20 0.44
▸ PSMB9 P28065 1/20 0.44
▸ CYP2C9 P11712 4/20 0.43
▸ CYP2C19 P33261 3/20 0.43
▸ LMNA P02545 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ CTRB1 P17538 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8100429 1.00 CTSL (0.48) CTSLCTSBATMTRPM8CYP3A4
SCHEMBL8104695 1.00 CTSL (0.48) CTSLCTSBATMTRPM8CYP3A4
SCHEMBL14725970 1.00 CTSL (0.48) CTSLCTSBATMTRPM8CYP3A4
SCHEMBL1701586 1.00 CTSL (0.48) CTSLCTSBATMTRPM8CYP3A4
SCHEMBL1709158 1.00 CTSL (0.48) CTSLCTSBATMTRPM8CYP3A4
SCHEMBL17452278 0.88 PSMB9 (0.55) CTSLCTSBATMTRPM8CYP3A4
SCHEMBL12052767 0.88 PSMB9 (0.55) CTSLCTSBATMTRPM8CYP3A4
SCHEMBL1709152 0.88 PSMB9 (0.55) CTSLCTSBATMTRPM8CYP3A4
SCHEMBL1701914 0.88 PSMB9 (0.55) CTSLCTSBATMTRPM8CYP3A4
SCHEMBL1709149 0.88 PSMB9 (0.55) CTSLCTSBATMTRPM8CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9657058-B2 Compounds for enzyme inhibition ONYX THERAPEUTICS, INC. (US) 2017-05-23 — — US disclosed
US-20150353601-A1 COMPOUNDS FOR ENZYME INHIBITION ONYX THERAPEUTICS INC (US) 2015-12-10 — — US disclosed
US-8735441-B2 Compounds for enzyme inhibition ONYX THERAPEUTICS, INC. (US) 2014-05-27 — — US disclosed
US-8431571-B2 Compounds for enzyme inhibition ONYX THERAPEUTICS, INC. (US) 2013-04-30 — — US disclosed
US-20130041008-A1 COMPOUNDS FOR ENZYME INHIBITION ONYX THERAPEUTICS, INC. (US) 2013-02-14 — — US disclosed
US-20130035297-A1 COMPOUNDS FOR ENZYME INHIBITION ONYX THERAPEUTICS, INC. (US) 2013-02-07 — — US disclosed
US-8357683-B2 Compounds for enzyme inhibition ONYX THERAPEUTICS, INC. (US) 2013-01-22 — — US disclosed
US-20120088762-A1 COMPOUNDS FOR ENZYME INHIBITION ONYX THERAPEUTICS, INC. (US) 2012-04-12 — — US disclosed
US-20120088762-A1 COMPOUNDS FOR ENZYME INHIBITION ONYX THERAPEUTICS, INC. (US) 2012-04-12 — — US disclosed
US-8080576-B2 Compounds for enzyme inhibition ONYX THERAPEUTICS, INC. (US) 2011-12-20 — — US disclosed
US-8080545-B2 Compounds for enzyme inhibition ONYX THERAPEUTICS, INC. (US) 2011-12-20 — — US disclosed
US-8080545-B2 Compounds for enzyme inhibition ONYX THERAPEUTICS, INC. (US) 2011-12-20 — — US disclosed
US-8080576-B2 Compounds for enzyme inhibition ONYX THERAPEUTICS, INC. (US) 2011-12-20 — — US disclosed
US-20100144649-A1 COMPOUNDS FOR ENZYME INHIBITION ONYX THERAPEUTICS, INC. (US) 2010-06-10 — — US disclosed
US-20100144649-A1 COMPOUNDS FOR ENZYME INHIBITION ONYX THERAPEUTICS, INC. (US) 2010-06-10 — — US disclosed
US-20100144648-A1 COMPOUNDS FOR ENZYME INHIBITION ONYX THERAPEUTICS, INC. (US) 2010-06-10 — — US disclosed
US-20100144648-A1 COMPOUNDS FOR ENZYME INHIBITION ONYX THERAPEUTICS, INC. (US) 2010-06-10 — — US disclosed
US-7691852-B2 Compounds for enzyme inhibition ONYX THERAPEUTICS, INC. (US) 2010-04-06 — — US disclosed
US-20070293465-A1 Compounds for enzyme inhibition PROTEOLIX, INC. (US) 2007-12-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088762-A1 COMPOUNDS FOR ENZYME INHIBITION PSME1, PSMB1, PSME3 CTSL 724/4885CTSB 168/4885ATM 3102/4885
US-20150353601-A1 COMPOUNDS FOR ENZYME INHIBITION PSME1, PSMB1, PSME3 CTSL 724/4885CTSB 168/4885ATM 3102/4885
US-20130041008-A1 COMPOUNDS FOR ENZYME INHIBITION PSME1, PSMB1, PSME3 CTSL 724/4885CTSB 168/4885ATM 3102/4885
US-20070293465-A1 Compounds for enzyme inhibition PSME1, PSMB1, PSME3 CTSL 724/4885CTSB 168/4885ATM 3102/4885
US-20100144648-A1 COMPOUNDS FOR ENZYME INHIBITION PSME1, PSMB1, PSME3 CTSL 724/4885CTSB 168/4885ATM 3102/4885
US-20130035297-A1 COMPOUNDS FOR ENZYME INHIBITION PSME1, PSMB1, PSME3 CTSL 724/4885CTSB 168/4885ATM 3102/4885
US-20100144649-A1 COMPOUNDS FOR ENZYME INHIBITION PSME1, PSMB1, PSME3 CTSL 724/4885CTSB 168/4885ATM 3102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.